Shire's serial story
How Baxalta deal will help Shire evaluate new M&A opportunities
But at least equally important to Shire is how Baxalta can help it evaluate additional deals that will help extend and grow its brand-new hematology, immunology and cancer franchises.
"We've made no qualms that Shire wants to be the leader in rare diseases, and we will be back out on the deal trail after we've paid off some debt," said Shire CEO Flemming Ornskov.
The proposed deal announced Jan. 11 brings to a close Shire's five-month pursuit of Baxalta with a $32 billion offer consisting of $18 in cash and 0.1482 Shire ADSs per Baxalta share. The companies said